Anavex Life Sciences Corp (AVXL)

[Investor2014]

Seems the various cognitive and functional tests in the early stages of AD are very imprecise.

Anavex have gone for the ‘traditional’ measures in their P2/3 trial in AD as primary endpoints. With the genetic biomarkers as secondary.

Hope A2-73 sticks with powerful enough effect in mild AD to be stat sig.

What the discussion really shows, I think is that finding dependable biological markers of developing AD is critical to both early diagnosis and to determining the effect of a treatment in trials.